Hostname: page-component-7b9c58cd5d-hxdxx Total loading time: 0 Render date: 2025-03-20T18:14:52.019Z Has data issue: false hasContentIssue false
  • English
  • Français

“Meta-guidelines” for the management of patients with schizophrenia

Published online by Cambridge University Press:  16 April 2013

Stephen M. Stahl ,
Debbi A. Morrissette ,
Leslie Citrome ,
Stephen R. Saklad ,
Michael A. Cummings ,
Jonathan M. Meyer ,
Jennifer A. O'Day ,
Laura J. Dardashti  and
Katherine D. Warburton
Stephen M. Stahl*
Affiliation:
Department of Psychiatry, University of California–San Diego, San Diego, California, USA Department of Psychiatry, University of Cambridge, Cambridge, UK Neuroscience Education Institute, Carlsbad, California, USA California Department of State Hospitals, Sacramento, California, USA
Debbi A. Morrissette
Affiliation:
Neuroscience Education Institute, Carlsbad, California, USA
Leslie Citrome
Affiliation:
New York Medical College, Valhalla, New York, USA
Stephen R. Saklad
Affiliation:
San Antonio State Hospital, Texas Department of State Health Services, San Antonio, Texas, USA College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, Austin, Texas, USA School of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA
Michael A. Cummings
Affiliation:
California Department of State Hospitals, Sacramento, California, USA
Jonathan M. Meyer
Affiliation:
Department of Psychiatry, University of California–San Diego, San Diego, California, USA California Department of State Hospitals, Sacramento, California, USA
Jennifer A. O'Day
Affiliation:
California Department of State Hospitals, Sacramento, California, USA
Laura J. Dardashti
Affiliation:
California Department of State Hospitals, Sacramento, California, USA
Katherine D. Warburton
Affiliation:
California Department of State Hospitals, Sacramento, California, USA
*
*Address for correspondence: Stephen M. Stahl, MD, PhD, 1930 Palomar Point Way, Suite 103, Carlsbad, CA 92008, USA. (Email smstahl@neiglobal.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

Guidelines for treating various conditions can be helpful in setting practice standards, but the presence of several sets of guidelines from different countries, experts, and settings, written at different times, can also create confusion. Here we provide a “guideline of guidelines” for the treatment of schizophrenia, or “meta-guidelines,” which not only reconcile the various existing standards but also update them to include the use of several newer agents, most of which were marketed following the publication of existing standards.

Keywords

Assessmentacutemaintenanceantipsychoticsdepot
Type
Guidelines
Information
CNS Spectrums , Volume 18 , Issue 3 , June 2013 , pp. 150 - 162
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Washington, DC: American Psychiatric Association; 2004.Google Scholar
2.American Psychiatric Association. Treating Schizophrenia: A Quick Reference Guide. Washington, DC: American Psychiatric Association; 2004.Google Scholar
3.Kane, JM, Leucht, S, Carpenter, D, etal. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003; 64(suppl 12): 5–19.Google ScholarPubMed
4.Moore, TA, Buchanan, RW, Buckley, PF, etal. The Texas Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007; 68(11): 1751–1762.CrossRefGoogle ScholarPubMed
5.Dixon, L, Perkins, D, Calmes, C. Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Association; 2009.CrossRefGoogle Scholar
6.Buchanan, RW, Kreyenbuhl, J, Kelly, DL, etal. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 71–93.CrossRefGoogle ScholarPubMed
7.Dixon, LB, Dickerson, F, Bellack, AS, etal. The 2009 PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010; 36(1): 48–70.CrossRefGoogle ScholarPubMed
8.Kreyenbuhl, J, Buchanan, RW, Dickerson, FB, etal. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010; 36(1): 94–103.CrossRefGoogle ScholarPubMed
9.Stahl, SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand. 2010; 122: 440–441.CrossRefGoogle Scholar
10.Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125: 349–351.CrossRefGoogle Scholar
11.Stahl, SM. The tyranny of the majority and the interchangeability of drugs. Acta Psychiatr Scand. 2013; 127: 4–5.CrossRefGoogle ScholarPubMed
12.Stahl, SM, Morrissette, DA. Should high dose or very long term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In: Ritsner MS, ed. Polypharmacy in Psychiatry Practice, Volume I: Use of Polypharmacy in the “Real World”. Dordrecht, The Netherlands: Springer Science; 2013.Google Scholar
13.Ritsner, MS, ed. Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies. Dordrecht, The Netherlands: Springer Science; 2013.CrossRefGoogle Scholar
14.Ritsner, MS, ed. Polypharmacy in Psychiatry Practice, Volume 2: Use of Polypharmacy in the “Real World.” Dordrecht, The Netherlands: Springer Science; 2013.Google Scholar
15.Stahl, SM. Stahl's Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.Google Scholar
16.National Institutes of Mental Health Psychoactive Drug Screening Program. http://pdsp.med.unc.edu/indexR.html. Accessed August 2012.Google Scholar